PATTENZYME · Sequential and selective patterning of enzymes in modular electrochemical based biorreactor for continuos production of pharmaceutical materials
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2022-03-17 → 2024-03-16
- EU contribution
- €184,591
- Participants
- 1
- Scheme
- MSCA-IF
Lines connect the coordinator with its partners.
Results in brief
Sequential and selective patterning of enzymes in modular electrochemical based biorreactor for continuos production of pharmaceutical materials
PATTENZYME addresses a gap in the state of the art in the preparation of pharmaceutical materials by using electrochemical approaches for the targeted and selective immobilization of bio/catalysts in modular 3D printed reactors. The pharmaceutical industry faces a significant challenge in its reliance on batch processes with synthesis of active pharmaceutical ingredients occurring via individual reactions, methods that are not well suited to modern, flexible, manufacturing processes that need to be agile and responsive to changing needs. PATTENZYME prepares a modular bioreactor for the controlled delivery of H2O2 in 3D-printed flow reactors for the selective synthesis of pharmaceutical materials in a stand-alone environment. PATTENZYME is an original and innovative project which 3D printed reactors with catalysts incorporated in a patterned manner in the channels that utilizes continuous flow technology for the controlled delivery of the oxidant as the first step in a cascade reaction. In the subsequent step, bio/catalysts will be utilized for the catalytic oxidation of substrates for the production of pharmaceutical materials. Overall objectives: Preparation and characterization of NPG Optimization of immobilization of UPO and of Mn salen on modified NPG. Reaction/flow modelling and modelling of patterning and loading of catalysts. Assembly of 3D printed flow cells that incorporate immobilized bio/catalysts in aqueous and non-aqueous solutions.
Data: CORDIS, © European Union
Project objective
The pharmaceutical industry is a major industrial sector in the EU (annual sales of €130 billion). In contrast to other manufacturing sectors, the sector faces a significant challenge in its reliance on batch processes, with synthesis of active pharmaceutical ingredients (API) occurring via individual reaction steps. Such an approach is not well suited to modern manufacturing methods, and reflects a gap in the state of the art in the manufacture of APIs, where flexible plug and play modular systems to manufacture the drug product from raw materials when they are needed reactors are required. PATTENZYME will address this gap by using electrochemical approaches for the targeted and selective immobilization of bio/catalysts in modular 3D printed bio/reactors. The project will utilise a multi-disciplinary approach that combine electrode preparation and characterisation, modelling of fluid flow and rates of reaction, enzyme immobilisation and characterisation with the preparation and characterisation of 3D printed flow reactors. Specifically, PATTENZYME will immobilize laccase on high surface area supports in 3D-printed reactors for the production and controlled delivery of H2O2 to spatially patterned bio/catalysts for enantio/regio selective oxidation reactions with the goal of developing a bio/reactor for the enantioselective oxidation of omeprazol sulphide to esomeprazole. The bio/catalysts will be immobilised on nanoporous gold electrodes at specific locations in the channels of the bio/reactor. Detailed modelling and characterisation studies will be performed to ascertain the optimal location of the catalysts, the architecture of the channels and the flow rate. 3D printed prototype reactors will be produced and characterised to prepare the optimal system for the oxidation of omeprazol sulphide. PATTENZYME will provide advanced training in a multidisciplinary training programme that is informed by leading expertise in the pharmaceutical sector.
Original text from CORDIS.
Participants
- UNIVERSITY OF LIMERICK · LimerickCoordinatorIreland
Links
Data: CORDIS, © European Union